Immunome Inc., a biotechnology company specializing in targeted cancer therapies, has announced the granting of inducement awards under its 2024 Inducement Plan. On August 1, 2025, the company's Compensation Committee approved non-statutory stock options for five new employees, allowing them to purchase a total of 39,000 shares of common stock. The exercise price for these stock options is set at $10.59 per share, reflecting the company's closing sales price on the grant date. The options will vest over a period of four years, with 25% vesting on the first anniversary of the vesting commencement date and the remaining shares vesting monthly over the next 36 months. These inducement grants are offered in line with Nasdaq Listing Rule 5635(c)(4).